The role of mTOR in age-related diseases

References

• Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721–6.
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975;28:727–32.
   PubMed Web of Science ®Google Scholar
• Singh K, Sun S, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action. J Antibiot 1979;32:630–45.
   PubMed Web of Science ®Google Scholar
• Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001;93:1517–9.
   PubMed Web of Science ®Google Scholar
• Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55:48–51.
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992;176:751–60.
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144:251–8.
   PubMed Web of Science ®Google Scholar
• Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 2008;9:635–43.
   PubMed Web of Science ®Google Scholar
• Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22:viii61–5.
   PubMed Web of Science ®Google Scholar
• Eng CP, Sehgal SN, Vézina C. Activity of Rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984;37:1231–7.
   PubMed Web of Science ®Google Scholar
• Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756–8.
   PubMed Web of Science ®Google Scholar
• Vellai T, Takacs-Vellai K, Zhang Y, et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003;426:620.
   PubMed Web of Science ®Google Scholar
• Kapahi P, Zid BM, Harper T, et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004;14:885–90.
   PubMed Web of Science ®Google Scholar
• Kaeberlein M, Powers RW, Steffen KK, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005;310:1193–6.
   PubMed Web of Science ®Google Scholar
• Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392–5.
   PubMed Web of Science ®Google Scholar
• Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66:191–201.
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010;176:2092–7.
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011;10:4230–6.
   PubMed Web of Science ®Google Scholar
• Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell 2012;11:675–82.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009;2:ra75.
   PubMed Web of Science ®Google Scholar
• Hartwell LH. Macromolecule synthesis in temperature-sensitive mutants of yeast. J Bacteriol 1967;93:1662–70.
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253–62.
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva N, Hall M. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:905–9.
   PubMed Web of Science ®Google Scholar
• Lench NJ, Macadam R, Markham AF. The human gene encoding FKBP-rapamycin associated protein (FRAP) maps to chromosomal band 1p36.2. Hum Genet 1997;99:547–9.
   PubMed Web of Science ®Google Scholar
• Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815–22.
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35–43.
   PubMed Web of Science ®Google Scholar
• Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 1994;91:12574–8.
   PubMed Web of Science ®Google Scholar
• Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995;270:50.
   PubMed Web of Science ®Google Scholar
• Baretić D, Williams RL. The structural basis for mTOR function. Semin Cell Dev Biol 2014; 36:91–101.
   PubMed Web of Science ®Google Scholar
• Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996;273:239–42.
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457–68.
   PubMed Web of Science ®Google Scholar
• Smithson LJ, Gutmann DH. Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival. Genes Dev 2016;30:1383–8.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003;11:895–904.
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177–89.
   PubMed Web of Science ®Google Scholar
• Kaizuka T, Hara T, Oshiro N, et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem 2010;285:20109–16.
   PubMed Web of Science ®Google Scholar
• Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25:903–15.
   PubMed Web of Science ®Google Scholar
• Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873–86.
   PubMed Web of Science ®Google Scholar
• Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003;278:15461–4.
   PubMed Web of Science ®Google Scholar
• Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 2003;13:654–8.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Gygi SP, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001;15:2852–64.
   PubMed Web of Science ®Google Scholar
• Levy S, Avni D, Hariharan N, et al. Oligopyrimidine tract at the 5′ end of mammalian ribosomal protein mRNAs is required for their translational control. Proc Natl Acad Sci USA 1991;88:3319–23.
   PubMed Web of Science ®Google Scholar
• Lahr RM, Fonseca BD, Ciotti GE, et al. La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs. Elife 2017;6:e24146.
   PubMed Web of Science ®Google Scholar
• Hong S, Freeberg MA, Han T, et al. LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs. Elife 2017;6:e25237.
   PubMed Web of Science ®Google Scholar
• Mayer C, Zhao J, Yuan X, Grummt I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 2004;18:423–34.
   PubMed Web of Science ®Google Scholar
• Hannan KM, Brandenburger Y, Jenkins A, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 2003;23:8862–77.
   PubMed Web of Science ®Google Scholar
• Shor B, Wu J, Shakey Q, et al. Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells. J Biol Chem 2010;285:15380–92.
   PubMed Web of Science ®Google Scholar
• Tsang CK, Liu H, Zheng XFS. mTOR binds to the promoters of RNA polymerase I- And III-transcribed genes. Cell Cycle 2010;9:953–7.
   PubMed Web of Science ®Google Scholar
• Jung CH, Jun CB, Ro S-H, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009;20:1992–2003.
   PubMed Web of Science ®Google Scholar
• Ganley IG, Lam DH, Wang J, et al. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 2009;284:12297–305.
   PubMed Web of Science ®Google Scholar
• Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol 2010;20:1093–8.
   PubMed Web of Science ®Google Scholar
• Wan W, Liu W. MTORC1 regulates autophagic membrane growth by targeting WIPI2. Autophagy 2019;15:742–43.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhai B, Gygi SP, Goldberg AL. MTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proc Natl Acad Sci USA 2015;112:15790–7.
   PubMed Web of Science ®Google Scholar
• Eid W, Dauner K, Courtney KC, et al. mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc Natl Acad Sci USA 2017;114:7999–8004.
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008;8:224–36.
   PubMed Web of Science ®Google Scholar
• Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004;53:2748–56.
   PubMed Web of Science ®Google Scholar
• Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171–83.
   PubMed Web of Science ®Google Scholar
• Peterson TR, Sengupta SS, Harris TE, et al. MTOR complex 1 regulates lipin 1 localization to control the srebp pathway. Cell 2011;146:408–20.
   PubMed Web of Science ®Google Scholar
• Cunningham JT, Rodgers JT, Arlow DH, et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007;450:736–40.
   PubMed Web of Science ®Google Scholar
• Schieke SM, Phillips D, McCoy JP, et al. The mammalian target of Rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006;281:27643–52.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013;339:1323–8.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Hoxhaj G, Ricoult SJH, et al. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 2016;351:728–33.
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Gadi N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem 2008;283:34495–9.
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004–14.
   PubMed Web of Science ®Google Scholar
• West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998;17:769–80.
   PubMed Web of Science ®Google Scholar
• He L, Gomes AP, Wang X, et al. mTORC1 promotes metabolic reprogramming by the suppression of GSK3-dependent Foxk1 phosphorylation. Mol Cell 2018;70:949–60.e4.
   PubMed Web of Science ®Google Scholar
• Dang CV. A time for MYC: metabolism and therapy. Cold Spring Harb Symp Quant Biol 2016;81:79–83.
   PubMedGoogle Scholar
• Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648–57.
   PubMed Web of Science ®Google Scholar
• Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003;13:1259–68.
   PubMed Web of Science ®Google Scholar
• Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol 2005;15:702–13.
   PubMed Web of Science ®Google Scholar
• Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179–93.
   PubMed Web of Science ®Google Scholar
• Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008;320:1496–501.
   PubMed Web of Science ®Google Scholar
• Rebsamen M, Pochini L, Stasyk T, et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 2015;519:477–81.
   PubMed Web of Science ®Google Scholar
• Jung J, Genau HM, Behrends C. Amino acid-dependent mTORC1 regulation by the lysosomal membrane protein SLC38A9. Mol Cell Biol 2015;35:2479–94.
   PubMed Web of Science ®Google Scholar
• Wolfson RL, Chantranupong L, Wyant GA, et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature 2017;543:438–42.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Knockenhauer KE, Wolfson RL, et al. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science 2016;351:53–8.
   PubMed Web of Science ®Google Scholar
• Wolfson RL, Chantranupong L, Saxton RA, et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 2016;351:43–8.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Chantranupong L, Knockenhauer KE, et al. Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature 2016;536:229–33.
   PubMed Web of Science ®Google Scholar
• Chantranupong L, Scaria SM, Saxton RA, et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell 2016;165:153–64.
   PubMed Web of Science ®Google Scholar
• Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577–90.
   PubMed Web of Science ®Google Scholar
• Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214–26.
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005;102:8204–9.
   PubMed Web of Science ®Google Scholar
• Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN Transcription by p53. Mol Cell 2001;8:317–25.
   PubMed Web of Science ®Google Scholar
• Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008;134:451–60.
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893–904.
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005;30:35–42.
   PubMed Web of Science ®Google Scholar
• Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399–403.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim D-H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296–302.
   PubMed Web of Science ®Google Scholar
• Stuttfeld E, Aylett CH, Imseng S, et al. Architecture of the human mTORC2 core complex. Elife 2018;7:e33101.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 2005;307:1098–1101.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125–37.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006;11:859–71.
   PubMed Web of Science ®Google Scholar
• Pearce LR, Sommer EM, Sakamoto K, et al. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J 2011;436:169–79.
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Inoki K, Yang Q, et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. Embo J 2008;27:1919–31.
   PubMed Web of Science ®Google Scholar
• García-Martínez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008;416:375–85.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122–8.
   PubMed Web of Science ®Google Scholar
• Ebner M, Sinkovics B, Szczygieł M, et al. Localization of mTORC2 activity inside cells. J Cell Biol 2017;216:343–53.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 2011;44:304–16.
   PubMed Web of Science ®Google Scholar
• Wang B, Jie Z, Joo D, et al. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature 2017;545:365–9.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009;29:5657–70.
   PubMed Web of Science ®Google Scholar
• Glidden EJ, Gray LG, Vemuru S, et al. Multiple site acetylation of rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. J Biol Chem 2012;287:581–8.
   PubMed Web of Science ®Google Scholar
• Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by Association with the Ribosome. Cell 2011;144:757–68.
   PubMed Web of Science ®Google Scholar
• Hatano T, Morigasaki S, Tatebe H, et al. Fission yeast Ryh1 GTPase activates TOR complex 2 in response to glucose. Cell Cycle 2015;14:848–56.
   PubMed Web of Science ®Google Scholar
• Cai W, Andres DA, Reiner DJ. MTORC2 Is required for Rit-mediated oxidative stress resistance. PLOS One 2014;9:e115602.
   PubMed Web of Science ®Google Scholar
• Saci A, Cantley LC, Carpenter CL. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 2011;42:50–61.
   PubMed Web of Science ®Google Scholar
• Byun J-K, Choi Y-K, Kim J-H, et al. A positive feedback loop between Sestrin2 and mTORC2 is required for the survival of glutamine-depleted lung cancer cells. Cell Rep 2017;20:586–99.
   PubMed Web of Science ®Google Scholar
• Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001;15:1406–18.
   PubMed Web of Science ®Google Scholar
• Deprez J, Vertommen D, Alessi DR, et al. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem 1997;272:17269–75.
   PubMed Web of Science ®Google Scholar
• Barthel A, Okino ST, Liao J, et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem 1999;274:20281–6.
   PubMed Web of Science ®Google Scholar
• Cerniglia GJ, Dey S, Gallagher-Colombo SM, et al. The PI3K/Akt pathway regulates oxygen metabolism via pyruvate dehydrogenase (PDH)-E1α phosphorylation. Mol Cancer Ther 2015;14:1928–38.
   PubMed Web of Science ®Google Scholar
• Masui K, Tanaka K, Akhavan D, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab 2013;18:726–39.
   PubMed Web of Science ®Google Scholar
• Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011;108:4129–34.
   PubMed Web of Science ®Google Scholar
• Zha X, Wang F, Wang Y, et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 2011;71:13–8.
   PubMed Web of Science ®Google Scholar
• Masui K, Cavenee WK, Mischel PS. Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 2014;25:364–73.
   PubMed Web of Science ®Google Scholar
• Guri Y, Colombi M, Dazert E, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell 2017;32:807–23.e12.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wallace M, Sanchez-Gurmaches J, et al. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nat Commun 2016;7:11365.
   PubMed Web of Science ®Google Scholar
• Kumar A, Harris TE, Keller SR, et al. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 2008;28:61–70.
   PubMed Web of Science ®Google Scholar
• Hagiwara A, Cornu M, Cybulski N, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012;15:725–38.
   PubMed Web of Science ®Google Scholar
• Betz C, Stracka D, Prescianotto-Baschong C, et al. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci USA 2013;110:12526–34.
   PubMed Web of Science ®Google Scholar
• Yuan M, Pino E, Wu L, et al. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol Chem 2012;287:29579–88.
   PubMed Web of Science ®Google Scholar
• Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003;423:550–5.
   PubMed Web of Science ®Google Scholar
• Rosario FJ, Kanai Y, Powell TL, Jansson T. Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. J Physiol 2013;591:609–25.
   PubMed Web of Science ®Google Scholar
• Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol Cell 2017;67:128–38.e7.
   PubMed Web of Science ®Google Scholar
• Saha A, Connelly S, Jiang J, et al. Akt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesis. Mol Cell 2014;55:264–76.
   PubMed Web of Science ®Google Scholar
• Wang W, Fridman A, Blackledge W, et al. The phosphatidylinositol 3-kinase/Akt cassette regulates purine nucleotide synthesis. J Biol Chem 2009;284:3521–8.
   PubMed Web of Science ®Google Scholar
• Lamming DW, Mihaylova MM, Katajisto P, et al. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell 2014;13:911–7.
   PubMed Web of Science ®Google Scholar
• Nojima A, Yamashita M, Yoshida Y, et al. Haploinsufficiency of Akt1 prolongs the lifespan of mice. PLOS One 2013;8:e69178.
   PubMed Web of Science ®Google Scholar
• Shigihara N, Fukunaka A, Hara A, et al. Human IAPP-induced pancreatic β cell toxicity and its regulation by autophagy. J Clin Invest 2014;124:3634–44.
   PubMed Web of Science ®Google Scholar
• Ebato C, Uchida T, Arakawa M, et al. Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. Cell Metab 2008;8:325–32.
   PubMed Web of Science ®Google Scholar
• Jung HS, Chung KW, Won Kim J, et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab 2008;8:318–24.
   PubMed Web of Science ®Google Scholar
• Bartolome A, Guillen C, Benito M. Autophagy plays a protective role in endoplasmic reticulum stress-mediated pancreatic β cell death. Autophagy 2012;8:1757–68.
   PubMed Web of Science ®Google Scholar
• Shigeyama Y, Kobayashi T, Kido Y, et al. Biphasic Response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008;28:2971–9.
   PubMed Web of Science ®Google Scholar
• Hernández MG, Aguilar AG, Burillo J, et al. Pancreatic β cells overexpressing hIAPP impaired mitophagy and unbalanced mitochondrial dynamics. Cell Death Dis 2018;9:481.
   PubMed Web of Science ®Google Scholar
• Bartolomé A, Kimura-Koyanagi M, Asahara SI, et al. Pancreatic β-cell failure mediated by mTORC1 hyperactivity and autophagic impairment. Diabetes 2014;63:2996–3008.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron 1991;6:487–98.
   PubMed Web of Science ®Google Scholar
• Hardy J, Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184–85.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913–7.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 1986;99:1807–10.
   PubMed Web of Science ®Google Scholar
• Patrick GN, Zukerberg L, Nikolic M, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615–22.
   PubMed Web of Science ®Google Scholar
• Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011;27:3–20.
   PubMed Web of Science ®Google Scholar
• Reijmer YD, van den Berg E, Ruis C, et al. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab Res Rev 2010;26:507–19.
   PubMed Web of Science ®Google Scholar
• Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. J Am Med Assoc 1995;273:942.
   PubMed Web of Science ®Google Scholar
• Duelli R, Kuschinsky W. Brain glucose transporters: relationship to local energy demand. News Physiol Sci 2001;16:71–6.
   PubMedGoogle Scholar
• Liu Y, Liu F, Grundke-Iqbal I, et al. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 2011;225:54–62.
   PubMed Web of Science ®Google Scholar
• Norambuena A, Wallrabe H, Cao R, et al. A novel lysosome‐to‐mitochondria signaling pathway disrupted by amyloid‐β oligomers. Embo J 2018;37:e100241.
   PubMed Web of Science ®Google Scholar
• Josselyn SA, Frankland PW. mTORC2: actin on your memory. Nat Neurosci 2013;16:379–380.
   PubMed Web of Science ®Google Scholar
• Takei N, Nawa H. mTOR signaling and its roles in normal and abnormal brain development. Front Mol Neurosci 2014;7:28.
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 2005;93:105–17.
   PubMed Web of Science ®Google Scholar
• Caccamo A, Maldonado MA, Majumder S, et al. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 2011;286:8924–32.
   PubMed Web of Science ®Google Scholar
• Gupta A, Dey CS. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 2012;23:3882–98.
   PubMed Web of Science ®Google Scholar
• O'Neill C, Kiely AP, Coakley MF, et al. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem Soc Trans 2012;40:721–7.
   PubMed Web of Science ®Google Scholar
• O’ Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol 2013;48:647–53.
   PubMed Web of Science ®Google Scholar
• An W-L, Cowburn RF, Li L, et al. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 2003;163:591–607.
   PubMed Web of Science ®Google Scholar
• Hamano T, Gendron TF, Causevic E, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 2008;27:1119–30.
   PubMed Web of Science ®Google Scholar
• Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLOS One 2010;5:e9979.
   PubMed Web of Science ®Google Scholar
• Cassano T, Magini A, Giovagnoli S, et al. Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. Exp Neurol 2019;311:88–105.
   PubMed Web of Science ®Google Scholar
• Tramutola A, Lanzillotta C, Barone E, et al. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Transl Neurodegener 2018;7:1–22.
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889–909.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu W, Lu Y, et al. Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy 2018;14:845–61.
   PubMed Web of Science ®Google Scholar
• Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with lewy body disease and in models of alpha-synucleinopathy. PLOS One 2010;5:e9313.
   PubMed Web of Science ®Google Scholar
• Gao S, Duan C, Gao G, et al. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J Biochem Cell Biol 2015;64:25–33.
   PubMed Web of Science ®Google Scholar
• Jiang TF, Zhang YJ, Zhou HY, et al. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. J Neuroimmune Pharmacol 2013;8:356–69.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Sun Y, Watt JA, et al. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 2012;122:1354–67.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu C, Chen S, et al. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Cell Signal 2014;26:1680–9.
   PubMed Web of Science ®Google Scholar
• Meng T, Lin S, Zhuang H, et al. Recent progress in the role of autophagy in neurological diseases. Cell Stress 2019;3:141–61.
   PubMed Web of Science ®Google Scholar
• Martin DDO, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci 2015;38:26–35.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002;11:1107–17.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 2009;16:46–56.
   PubMed Web of Science ®Google Scholar
• Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004;36:585–95.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Chattopadhyay M, Whitelegge J, Selverstone Valentine J. SOD1 Aggregation and ALS: role of metallation states and disulfide status. Curr Top Med Chem 2012;12:2560–72.
   PubMed Web of Science ®Google Scholar
• Li A, Zhang X, Le W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008;4:290–3.
   PubMed Web of Science ®Google Scholar
• Morimoto N, Nagai M, Ohta Y, et al. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 2007;1167:112–7.
   PubMed Web of Science ®Google Scholar
• Rudnick ND, Griffey CJ, Guarnieri P, et al. Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS. Proc Natl Acad Sci USA 2017;114:E8294–303.
   PubMed Web of Science ®Google Scholar
• An T, Shi P, Duan W, et al. Oxidative stress and autophagic alteration in brainstem of SOD1-G93A mouse model of ALS. Mol Neurobiol 2014;49:1435–48.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li L, Chen S, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy 2011;7:412–25.
   PubMed Web of Science ®Google Scholar
• Staats KA, Hernandez S, Schönefeldt S, et al. Rapamycin increases survival in ALS mice lacking mature lymphocytes. Mol Neurodegener 2013;8:31.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the Origin of Cancer Cells. Science 1956;123:309–14.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Ramapriyan R, Caetano MS, Barsoumian HB, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther 2019;195:162–71.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11–20.
   PubMed Web of Science ®Google Scholar
• Buller CL, Loberg RD, Fan M-H, et al. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol 2008;295:C836–43.
   PubMed Web of Science ®Google Scholar
• Tran Q, Lee H, Park J, et al. Targeting cancer metabolism – revisiting the Warburg effects. Toxicol Res 2016;32:177–93.
   PubMed Web of Science ®Google Scholar
• Porstmann T, Santos CR, Lewis C, et al. A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Biochem Soc Trans 2009;37:278–83.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, et al. Delgoffe correspondence GM. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 2016;45:374–88.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kwok-Shing Ng P, Kucherlapati M, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 2017;31:820–32.e3.
   PubMed Web of Science ®Google Scholar
• Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014;4:554–63.
   PubMed Web of Science ®Google Scholar
• Cheng H, Zou Y, Ross JS, et al. RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov 2015;5:1262–70.
   PubMed Web of Science ®Google Scholar
• Joly MM, Hicks DJ, Jones B, et al. Rictor/mTORC2 drives progression and therapeutic resistance of HER2-amplified breast cancers. Cancer Res 2016;76:4752–64.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. MTOR signaling in growth control and disease. Cell 2012;149:274–93.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Myers AP, Cantley LC. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov 2013;3:1345–54.
   PubMed Web of Science ®Google Scholar
• Magaway C, Kim E, Jacinto E. Targeting mTOR and metabolism in cancer: lessons and innovations. Cells 2019;8:1584.
   Web of Science ®Google Scholar
• Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 2018;18:744–57.
   PubMed Web of Science ®Google Scholar
• Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614–36.
   PubMed Web of Science ®Google Scholar
• Raices M, Maruyama H, Dillin A, Karlseder J. Uncoupling of longevity and telomere length in C. elegans. PLOS Genet 2005;1:e30.
   PubMed Web of Science ®Google Scholar
• Parrinello S, Samper E, Krtolica A, et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 2003;5:741–7.
   PubMed Web of Science ®Google Scholar
• Tang DG, Tokumoto YM, Apperly JA, et al. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 2001;291:868–71.
   PubMed Web of Science ®Google Scholar
• Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956;11:298–300.
   PubMedGoogle Scholar
• Kitani K, Ivy GO. “I thought, thought, thought for four months in vain and suddenly the idea came” – an interview with Denham and Helen Harmanmitochondrial dysfunction and ageing. Biogerontology 2003;4:401–12.
   PubMed Web of Science ®Google Scholar
• Andziak B, O’Connor TP, Buffenstein R. Antioxidants do not explain the disparate longevity between mice and the longest-living rodent, the naked mole-rat. Mech Ageing Dev 2005;126:1206–12.
   PubMed Web of Science ®Google Scholar
• Corona M, Hughes KA, Weaver DB, Robinson GE. Gene expression patterns associated with queen honey bee longevity. Mech Ageing Dev 2005;126:1230–8.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006;5:2087–102.
   PubMed Web of Science ®Google Scholar
• McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998;8:351–4.
   PubMed Web of Science ®Google Scholar
• Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001;268:2784–91.
   PubMedGoogle Scholar
• Jacobs JJL, De Lange T. p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 2005;4:1364–8.
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593–602.
   PubMed Web of Science ®Google Scholar
• Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997–3007.
   PubMed Web of Science ®Google Scholar
• Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008–19.
   PubMed Web of Science ®Google Scholar
• Deng Q, Liao R, Wu B-L, Sun P. High intensity Ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004;279:1050–9.
   PubMed Web of Science ®Google Scholar
• Klein LE, Freeze BS, Smith AB, III, Horwitz SB. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 2005;4:501–7.
   PubMed Web of Science ®Google Scholar
• Roninson IB, Dokmanovic M. Induction of senescence-associated growth inhibitors in the tumor-suppressive function of retinoids. J Cell Biochem 2003;88:83–94.
   PubMed Web of Science ®Google Scholar
• Wang X, Wong SCH, Pan J, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 1998;58:5019–22.
   PubMed Web of Science ®Google Scholar
• López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013;153:1194–217.
   PubMed Web of Science ®Google Scholar
• Koga H, Kaushik S, Cuervo AM. Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res Rev 2011;10:205–15.
   PubMed Web of Science ®Google Scholar
• Walters H, Cox L. mTORC inhibitors as broad-spectrum therapeutics for age-related diseases. Int J Mol Sci 2018;19:2325.
   Web of Science ®Google Scholar
• Qian S-B, Zhang X, Sun J, et al. mTORC1 links protein quality and quantity control by sensing chaperone availability. J Biol Chem 2010;285:27385–95.
   PubMed Web of Science ®Google Scholar
• Selman C, Tullet JMA, Wieser D, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009;326:140–4.
   PubMed Web of Science ®Google Scholar
• Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008;14:959–65.
   PubMed Web of Science ®Google Scholar
• Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes 2012;61:1315–22.
   PubMed Web of Science ®Google Scholar
• Yang S-B, Tien A-C, Boddupalli G, et al. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012;75:425–36.
   PubMed Web of Science ®Google Scholar
• Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science 2010;328:321–6.
   PubMed Web of Science ®Google Scholar
• Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012;489:318–21.
   PubMed Web of Science ®Google Scholar
• Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325:201–4.
   PubMed Web of Science ®Google Scholar
• Carroll B, Nelson G, Rabanal-Ruiz Y, et al. Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing. J Cell Biol 2017;216:1949–57.
   PubMed Web of Science ®Google Scholar
• Laberge R-M, Sun Y, Orjalo AV, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol 2015;17:1049–61.
   PubMed Web of Science ®Google Scholar
• Herranz N, Gallage S, Mellone M, et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol 2015;17:1205–17.
   PubMed Web of Science ®Google Scholar
• Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 2015;21:1424–35.
   PubMed Web of Science ®Google Scholar
• Korolchuk VI, Miwa S, Carroll B, von Zglinicki T. Mitochondria in cell senescence: is mitophagy the weakest link? EBioMedicine 2017;21:7–13.
   PubMed Web of Science ®Google Scholar
• Morita M, Gravel S-P, Chénard V, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013;18:698–711.
   PubMed Web of Science ®Google Scholar
• Lerner C, Bitto A, Pulliam D, et al. Reduced mammalian target of rapamycin activity facilitates mitochondrial retrograde signaling and increases life span in normal human fibroblasts. Aging Cell 2013;12:966–77.
   PubMed Web of Science ®Google Scholar
• Yilmaz ÖH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–82.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Liu R, et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008;205:2397–408.
   PubMed Web of Science ®Google Scholar
• Gan B, Sahin E, Jiang S, et al. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA 2008;105:19384–9.
   PubMed Web of Science ®Google Scholar
• Jang Y-Y, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007;110:3056–63.
   PubMed Web of Science ®Google Scholar
• Yilmaz ÖH, Katajisto P, Lamming DW, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012;486:490–5.
   PubMed Web of Science ®Google Scholar
• Chen T, Shen L, Yu J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011;10:908–11.
   PubMed Web of Science ®Google Scholar
• Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc 2011;43:1583–92.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev 2015;29:93–102.
   Web of Science ®Google Scholar
• Nishino M, Boswell EN, Hatabu H, et al. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a paradigm. Oncologist 2015;20:1077–83.
   PubMed Web of Science ®Google Scholar